JP2015537010A5 - - Google Patents

Download PDF

Info

Publication number
JP2015537010A5
JP2015537010A5 JP2015542134A JP2015542134A JP2015537010A5 JP 2015537010 A5 JP2015537010 A5 JP 2015537010A5 JP 2015542134 A JP2015542134 A JP 2015542134A JP 2015542134 A JP2015542134 A JP 2015542134A JP 2015537010 A5 JP2015537010 A5 JP 2015537010A5
Authority
JP
Japan
Prior art keywords
methyl
oxy
ethyl
purine
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015542134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015537010A (ja
JP6297582B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2013/001394 external-priority patent/WO2014075392A1/en
Publication of JP2015537010A publication Critical patent/JP2015537010A/ja
Publication of JP2015537010A5 publication Critical patent/JP2015537010A5/ja
Application granted granted Critical
Publication of JP6297582B2 publication Critical patent/JP6297582B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015542134A 2012-11-16 2013-11-15 ヒトホスファチジルイノシトール3−キナーゼデルタのプリン阻害剤 Expired - Fee Related JP6297582B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727416P 2012-11-16 2012-11-16
US61/727,416 2012-11-16
PCT/CN2013/001394 WO2014075392A1 (en) 2012-11-16 2013-11-15 Purine inhibitors of human phosphatidylinositol 3-kinase delta

Publications (3)

Publication Number Publication Date
JP2015537010A JP2015537010A (ja) 2015-12-24
JP2015537010A5 true JP2015537010A5 (enExample) 2016-12-22
JP6297582B2 JP6297582B2 (ja) 2018-03-20

Family

ID=50730541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542134A Expired - Fee Related JP6297582B2 (ja) 2012-11-16 2013-11-15 ヒトホスファチジルイノシトール3−キナーゼデルタのプリン阻害剤

Country Status (11)

Country Link
US (1) US9730940B2 (enExample)
EP (1) EP2920171B1 (enExample)
JP (1) JP6297582B2 (enExample)
KR (1) KR20150082613A (enExample)
CN (1) CN104918939B (enExample)
AU (1) AU2013347538B2 (enExample)
BR (1) BR112015011148A8 (enExample)
CA (1) CA2891009A1 (enExample)
MX (1) MX2015006191A (enExample)
RU (1) RU2658006C2 (enExample)
WO (1) WO2014075392A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
WO2015131773A1 (zh) * 2014-03-06 2015-09-11 上海海雁医药科技有限公司 作为食欲素受体拮抗剂的哌啶衍生物
CN104030998B (zh) * 2014-06-05 2015-11-18 华东师范大学 4-多氟烷基-4,5-二取代异噁唑衍生物及其制备方法
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
JP6715239B2 (ja) 2014-09-11 2020-07-01 ヤンセン ファーマシューティカ エヌ.ベー. 置換2−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用
EP3204379B1 (en) * 2014-10-10 2019-03-06 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
WO2017134053A1 (en) * 2016-02-04 2017-08-10 Chiesi Farmaceutici S.P.A. Pyrazole derivatives as phosphoinositide 3-kinases inhibitors
WO2017166104A1 (en) * 2016-03-30 2017-10-05 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
AU2017326487B2 (en) * 2016-09-14 2021-08-05 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
CN113620976B (zh) * 2020-05-09 2023-09-26 中国医学科学院药物研究所 噻唑并嘧啶类化合物及其制备方法、用途和药物组合物
JP7736782B2 (ja) * 2021-03-29 2025-09-09 株式会社カネカ (2-メチルピリミジン-5-イル)ボロン酸誘導体の製造方法
CN113072480B (zh) * 2021-04-13 2022-09-30 常州佳德医药科技有限公司 一种手性(-)-5-氮杂螺[2.4]庚烷-7-醇、制备方法及应用
WO2024083237A1 (en) * 2022-10-20 2024-04-25 Impact Therapeutics (Shanghai) , Inc Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT95516A (pt) * 1989-10-06 1991-08-14 Wellcome Found Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos
US5670501A (en) 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
DE60144277D1 (de) * 2000-04-25 2011-05-05 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
HRP20030047B1 (hr) * 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
SE0300456D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
EP1636207A1 (en) * 2003-06-12 2006-03-22 Novo Nordisk A/S Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase
CA2565037A1 (en) 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
ME02789B (me) 2006-08-08 2011-06-30 Millennium Pharm Inc Jedinjenja heteroarila korisna kao inhibitori e1 aktivirajućih enzima
AU2009269087A1 (en) * 2008-07-07 2010-01-14 Xcovery Holding Company Llc PI3K isoform selective inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
AU2011271462A1 (en) * 2010-06-30 2013-01-10 Amgen Inc. Nitrogen containing heterocyclic compounds as PIK3 -delta inhibitors
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
EP2616469B1 (en) * 2010-09-14 2016-10-26 Exelixis, Inc. 9h-purine compounds as pi3k-delta inhibitors and methods for their manufacture
TWI642670B (zh) 2010-09-14 2018-12-01 伊塞利克斯公司 Pi3k-德爾塔抑制劑以及其應用和生產方法
CN102838600A (zh) * 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂

Similar Documents

Publication Publication Date Title
RU2015122895A (ru) Пуриновые ингибиторы человеческой фосфатидилинозит 3-киназы дельта
US12331056B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
US12281101B2 (en) Bicyclic lactams and methods of use thereof
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
RU2015122894A (ru) Пуриновые ингибиторы фосфатидилинозитол-3-киназы дельта человека
KR101812357B1 (ko) Cdk4/6의 억제제로서의 피롤로피리미딘 화합물
JP2016502522A5 (enExample)
JP2015522002A5 (enExample)
TW202423440A (zh) Kras g12c突變蛋白的系鏈之雜環抑制劑及其用途
JP2021506941A5 (enExample)
WO2018218133A1 (en) Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
HRP20210177T1 (hr) Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
HRP20120105T1 (hr) Aminoheterociklički spojevi
JP2014506929A5 (enExample)
RU2020129785A (ru) Фармацевтические производные 6,5-гетеробициклического кольца
JP2015527399A5 (enExample)
JP2017505327A5 (enExample)
JP2021504380A5 (enExample)
AU2024332123A1 (en) Compositions comprising werner syndrome helicase inhibitors and methods of using the same
RU2016135637A (ru) 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение
RU2014123316A (ru) Ингибиторы фосфодиэстеразы типа 10а
WO2025194054A1 (en) Spirocyclic compounds as modulators of kras and uses thereof
WO2025217247A1 (en) Tethered spiro-heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
KR20230107291A (ko) PPARγ 조절제 및 사용 방법
US12180226B2 (en) Spirotricycle RIPK1 inhibitors and methods of uses thereof